查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1949506

合成血液代用品市場－全球產業規模、佔有率、趨勢、機會及預測（依產品、應用、來源、成分、地區及競爭格局分類），2021-2031年

Synthetic Blood Substitute Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Source, By Component, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球合成血液替代品市場預計將從 2025 年的 1,039 萬美元成長到 2031 年的 1,858 萬美元，複合年成長率為 10.17%。

這個領域主要包括合成療法，特別是基於血紅蛋白的氧載體和全氟碳乳劑，旨在模擬天然血液的氧氣運輸能力。其成長的主要驅動力是捐血血液固有的物流限制，例如保存期限有限以及持續的全球供不應求，這些都使得尋找穩定的替代方案變得迫切。這些根本性因素並非暫時的趨勢，而是旨在解決整個醫療保健系統中存在的各種不平等問題。例如，美國紅十字會報告稱，2024年7月全國血液庫存下降了超過25%，凸顯了對可靠的合成解決方案的巨大商業性需求。

市場概覽
預測期 2027-2031
市場規模：2025年 1039萬美元
市場規模：2031年 1858萬美元
複合年成長率：2026-2031年 10.17%
成長最快的細分市場 心血管疾病
最大的市場 北美洲

然而，嚴格的臨床安全監管壁壘嚴重阻礙了市場成長。主要障礙在於不良生理反應的發生，例如血管收縮和腎毒性，這些反應歷來會導致後期臨床試驗的終止。因此，證明其安全性與人血相當的挑戰限制了其廣泛的商業性應用。對於那些希望將產品從實驗研究階段推進到實際醫療應用階段的製造商而言，解決這些毒性問題是至關重要的。

市場促進因素

全球捐血長期短缺是推動全球合成血液替代品市場發展的主要因素。醫療系統難以維持日常和緊急醫療所需的血液庫存。而完全依賴自願捐血的物流脆弱性，又因季節性波動和公共衛生危機等因素而加劇了這項短缺。因此，血液採集量與臨床需求之間日益擴大的差距迫使醫院尋求可儲存的合成替代品，以擺脫對人類捐血者的依賴。英國國家醫療服務體系（NHS）血液和移植中心2025年6月的一項分析凸顯了這一關鍵缺口，該分析發現，英格蘭每年需要超過20萬名捐血者才能滿足不斷成長的需求，這凸顯了非生物輸血方案的緊迫性。

此外，軍事和國防領域的戰略需求是市場創新的關鍵驅動力，其中無需低溫運輸儲存的氧載體的研發尤為重要。國防機構正積極資助研發在敵對作戰環境中治療出血性休克的實用解決方案，因為在這些環境中，傳統的輸血在後勤上難以實現。這種作戰需求正推動對凍乾人工細胞等技術的巨額投資。例如，UM Ventures在2025年1月報告稱，生物技術開發商Callocyte獲得了美國國防部和國立衛生研究院1700萬美元的津貼，用於進一步開發其ErythroMer技術。同樣，在2025年，賓州州立大學的研究團隊獲得了270萬美元的津貼，用於推進模擬人類紅血球的合成血液替代品的研發。

市場挑戰

嚴格的臨床安全監管環境是全球合成血液替代品市場商業性成長的主要障礙。製造商始終難以證明其基於血紅蛋白的氧載體和全氟碳乳劑與天然人血一樣安全。許多後期臨床試驗因反覆出現嚴重的生理不利事件（例如血管收縮和腎毒性）而被迫中止。由於監管機構採用非劣效性標準，這些安全漏洞導致產品無法獲得強制性核准，從而有效地阻礙了其從實驗原型到可上市醫療解決方案的轉換。

天然血液輸注設定的極高安全標準進一步加劇了監管瓶頸。這些標準規定了合成替代血液必須達到的門檻，而嚴格的安全統計標準使得即使是毒性較小的合成替代血液也難以獲得核准。例如，根據血液和生物療法促進協會（AABB）的數據，2024年的主動監測數據顯示，紅血球輸注導致嚴重併發症（例如輸血相關性急性肺損傷（TRALI））的發生率僅為每10,000例輸血0.17例。如果合成替代血液未能展現出類似的低風險特性，則會導致監管機構拒絕核准上市，從而直接阻礙該行業的擴張。

市場趨勢

開發用於降低毒性的包封血紅蛋白囊泡是一項重要的發展趨勢，它解決了長期以來阻礙產業發展的安全問題。與會導致嚴重血管收縮和腎損傷的傳統遊離血紅素製劑不同，這種方法專注於將血紅蛋白包封在脂質雙層膜內，模擬天然紅血球的結構穩定性。透過保護血管內皮免受血紅蛋白的直接接觸，生產商可以有效減少先前阻礙監管部門核准的不良生理反應。這項結構創新目前正從理論研究走向人體臨床試驗。例如，MedEdge MEA在2025年5月報道稱，奈良醫科大學已啟動一項臨床試驗，向志願者注射100至400毫升血紅蛋白囊泡，以檢驗在緊急輸血中的安全性。

同時，轉向重組和基因改造血紅蛋白來源正在改變供應鏈，最大限度地減少對有限供體來源材料的依賴。利用合成生物學和精準發酵技術，研發人員正逐步擺脫從過期的人血或牛血中提取血紅蛋白的做法，轉而在受控的實驗室環境中生產生物同源蛋白。此舉消除了與生物採集相關的病原體傳播風險和供應限制，並實現了藥用級血紅蛋白的大規模生產，以滿足全球創傷護理需求。例如，2025年10月，UM Ventures宣布Crycea公司簽署了一項獨家許可協議，授權其使用專有的生物合成血紅蛋白技術，從而實現不依賴人血或動物血成分的氧載體的大規模生產。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球合成血液代用品市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品（血紅素基氧載體（HBOC）、全氟碳乳劑（PFC）、幹細胞衍生紅血球、其他）
    • 依應用領域（心血管疾病、惡性腫瘤、創傷、新生兒疾病、器官移植、孕產婦疾病、其他）
    • 依來源（人類血液來源、微生物來源的重組紅血球、合成聚合物、幹細胞、其他）
    • 依成分（紅血球代用品、血小板代用品、血漿代用品）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美合成血液替代品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲合成血液代用品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區合成血液代用品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲合成血液替代品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲合成血液替代品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球合成血液代用品市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Aurum Biosciences Ltd
  • Hemarina SA
  • Hemoglobin Oxygen Therapeutics LLC
  • SpheriTech Ltd
  • Kalocyte, Inc.
  • OPKO Health, Inc.
  • Prolong Pharmaceuticals, LLC
  • VisusMed Medical Center
  • Boston Pharmaceuticals, Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 25000

The Global Synthetic Blood Substitute Market is projected to expand from USD 10.39 Million in 2025 to USD 18.58 Million by 2031, registering a CAGR of 10.17%. This sector consists of artificial therapeutics, primarily hemoglobin-based oxygen carriers and perfluorocarbon emulsions, designed to replicate the oxygen-transport capabilities of natural blood. Growth is chiefly driven by the inherent logistical limitations of donor blood, such as restricted shelf-life, and persistent global supply shortages that generate an urgent need for stable alternatives. These foundational drivers address systemic healthcare gaps rather than transient trends; for example, the American Red Cross reported a national blood inventory decline of over 25% in July 2024, underscoring the critical commercial need for reliable synthetic solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 10.39 Million
Market Size 2031USD 18.58 Million
CAGR 2026-203110.17%
Fastest Growing SegmentCardiovascular Diseases
Largest MarketNorth America

However, market growth is significantly hindered by rigorous regulatory barriers related to clinical safety. The primary obstacle remains the occurrence of adverse physiological reactions, including vasoconstriction and renal toxicity, which have historically halted late-stage clinical trials. Consequently, the challenge of proving a safety profile equivalent to human blood limits widespread commercial adoption. Resolving these toxicity issues stands as the definitive hurdle for manufacturers seeking to advance products from experimental research into viable medical applications.

Market Driver

The chronic global scarcity of donor blood serves as the main catalyst for the Global Synthetic Blood Substitute Market, as healthcare systems struggle to sustain inventories sufficient for routine and emergency care. This shortage is intensified by the logistical vulnerability of relying exclusively on voluntary donations, which face frequent disruptions due to seasonal changes and public health crises. As a result, the expanding disparity between collection volumes and clinical needs compels hospitals to pursue shelf-stable artificial alternatives that remove dependence on human donors. Highlighting this critical gap, an analysis by NHS Blood and Transplant in June 2025 identified an annual shortfall of over 200,000 donors required to satisfy rising demand in England, emphasizing the urgent need for non-biological transfusion options.

Furthermore, strategic requirements from the military and defense sectors act as a significant accelerator for market innovation, with a priority on developing oxygen carriers that function without cold-chain storage. Defense agencies are actively financing research into field-ready solutions designed to treat hemorrhagic shock in harsh combat settings where traditional transfusions are logistically unfeasible. This operational necessity channels substantial investment toward technologies such as freeze-dried artificial cells. For instance, UM Ventures reported in January 2025 that biotech developer KaloCyte received $17 million in grants from the Department of Defense and National Institutes of Health to progress its ErythroMer technology. Similarly, in 2025, a research team at Penn State University secured a $2.7 million grant to advance synthetic blood substitutes mimicking human red blood cells.

Market Challenge

The rigorous regulatory landscape concerning clinical safety constitutes the primary obstacle to the commercial growth of the Global Synthetic Blood Substitute Market. Manufacturers face consistent difficulties in proving that hemoglobin-based oxygen carriers and perfluorocarbon emulsions can replicate the safety profile of natural human blood. The repeated incidence of severe adverse physiological effects, such as vasoconstriction and renal toxicity, has resulted in the cessation of numerous late-stage clinical trials. Since regulatory authorities enforce a standard of non-inferiority, these safety shortcomings prevent products from securing essential approvals, effectively halting the progression from experimental prototypes to marketable medical solutions.

This regulatory bottleneck is exacerbated by the exceptionally high safety benchmarks set by natural blood transfusions, which define the standards synthetic alternatives must achieve. The statistical criteria for safety are exacting, complicating the approval process for engineered substitutes that demonstrate even minimal toxicities. For example, according to the Association for the Advancement of Blood & Biotherapies (AABB), active surveillance data in 2024 indicated that the rate of serious complications like Transfusion-Related Acute Lung Injury (TRALI) for red blood cells was as low as 0.17 per 10,000 transfusions. The failure of synthetic candidates to exhibit a similarly low risk profile compels regulators to deny market authorization, thereby directly stifling industry expansion.

Market Trends

The development of encapsulated hemoglobin vesicles to mitigate toxicity is a pivotal trend addressing the safety failures that have historically impeded industry advancement. Unlike earlier free-hemoglobin solutions that induced severe vasoconstriction and renal injury, this approach focuses on enclosing hemoglobin within lipid bilayer membranes to replicate the structural stability of natural red blood cells. By protecting the vascular lining from direct hemoglobin contact, manufacturers are effectively lowering the adverse physiological reactions that previously hindered regulatory success. This structural innovation is now moving from theoretical research to human trials; for instance, MedEdge MEA reported in May 2025 that Nara Medical University launched a clinical trial administering 100 to 400 milliliters of these hemoglobin vesicles to volunteers to verify their safety for emergency transfusions.

Concurrently, the shift toward recombinant and genetically modified hemoglobin sources is transforming the supply chain by minimizing dependence on finite donor-derived raw materials. Utilizing synthetic biology and precision fermentation, developers are transitioning away from extracting hemoglobin from expired human or bovine blood to producing bio-identical proteins in controlled laboratory settings. This move eradicates the risks of pathogen transmission and supply constraints linked to biological collection, facilitating the scalable, pharmaceutical-grade production necessary to meet global trauma needs. Illustrating this progress, UM Ventures announced in October 2025 that Chrysea finalized an exclusive licensing agreement to deploy its biosynthetic hemoglobin technology, enabling the mass manufacture of oxygen carriers without relying on human or animal blood components.

Key Market Players

  • Aurum Biosciences Ltd
  • Hemarina SA
  • Hemoglobin Oxygen Therapeutics LLC
  • SpheriTech Ltd
  • Kalocyte, Inc.
  • OPKO Health, Inc.
  • Prolong Pharmaceuticals, LLC
  • VisusMed Medical Center
  • Boston Pharmaceuticals, Inc

Report Scope

In this report, the Global Synthetic Blood Substitute Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Synthetic Blood Substitute Market, By Product

  • Hemoglobin-Based Oxygen Carriers (HBOCs)
  • Perfluorocarbon Emulsions (PFCs)
  • Stem Cell-Derived Red Blood Cells
  • Others

Synthetic Blood Substitute Market, By Application

  • Cardiovascular Diseases
  • Malignant Neoplasma
  • Injuries
  • Neonatal Conditions
  • Organ Transplant
  • Maternal Condition
  • Others

Synthetic Blood Substitute Market, By Source

  • Human Blood
  • Microorganism Based Recombinant HB
  • Synthetic Polymers
  • Stem Cells
  • Others

Synthetic Blood Substitute Market, By Component

  • Red Blood Cell Substitutes
  • Platelet Substitutes
  • Plasma Substitutes

Synthetic Blood Substitute Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Synthetic Blood Substitute Market.

Available Customizations:

Global Synthetic Blood Substitute Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Synthetic Blood Substitute Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Hemoglobin-Based Oxygen Carriers (HBOCs), Perfluorocarbon Emulsions (PFCs), Stem Cell-Derived Red Blood Cells, Others)
    • 5.2.2. By Application (Cardiovascular Diseases, Malignant Neoplasma, Injuries, Neonatal Conditions, Organ Transplant, Maternal Condition, Others)
    • 5.2.3. By Source (Human Blood, Microorganism Based Recombinant HB, Synthetic Polymers, Stem Cells, Others)
    • 5.2.4. By Component (Red Blood Cell Substitutes, Platelet Substitutes, Plasma Substitutes)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Synthetic Blood Substitute Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Source
    • 6.2.4. By Component
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Synthetic Blood Substitute Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Source
        • 6.3.1.2.4. By Component
    • 6.3.2. Canada Synthetic Blood Substitute Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Source
        • 6.3.2.2.4. By Component
    • 6.3.3. Mexico Synthetic Blood Substitute Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Source
        • 6.3.3.2.4. By Component

7. Europe Synthetic Blood Substitute Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Source
    • 7.2.4. By Component
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Synthetic Blood Substitute Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Source
        • 7.3.1.2.4. By Component
    • 7.3.2. France Synthetic Blood Substitute Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Source
        • 7.3.2.2.4. By Component
    • 7.3.3. United Kingdom Synthetic Blood Substitute Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Source
        • 7.3.3.2.4. By Component
    • 7.3.4. Italy Synthetic Blood Substitute Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Source
        • 7.3.4.2.4. By Component
    • 7.3.5. Spain Synthetic Blood Substitute Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Source
        • 7.3.5.2.4. By Component

8. Asia Pacific Synthetic Blood Substitute Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Source
    • 8.2.4. By Component
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Synthetic Blood Substitute Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Source
        • 8.3.1.2.4. By Component
    • 8.3.2. India Synthetic Blood Substitute Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Source
        • 8.3.2.2.4. By Component
    • 8.3.3. Japan Synthetic Blood Substitute Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Source
        • 8.3.3.2.4. By Component
    • 8.3.4. South Korea Synthetic Blood Substitute Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Source
        • 8.3.4.2.4. By Component
    • 8.3.5. Australia Synthetic Blood Substitute Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Source
        • 8.3.5.2.4. By Component

9. Middle East & Africa Synthetic Blood Substitute Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Source
    • 9.2.4. By Component
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Synthetic Blood Substitute Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Source
        • 9.3.1.2.4. By Component
    • 9.3.2. UAE Synthetic Blood Substitute Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Source
        • 9.3.2.2.4. By Component
    • 9.3.3. South Africa Synthetic Blood Substitute Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Source
        • 9.3.3.2.4. By Component

10. South America Synthetic Blood Substitute Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Source
    • 10.2.4. By Component
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Synthetic Blood Substitute Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Source
        • 10.3.1.2.4. By Component
    • 10.3.2. Colombia Synthetic Blood Substitute Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Source
        • 10.3.2.2.4. By Component
    • 10.3.3. Argentina Synthetic Blood Substitute Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Source
        • 10.3.3.2.4. By Component

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Synthetic Blood Substitute Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Aurum Biosciences Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Hemarina SA
  • 15.3. Hemoglobin Oxygen Therapeutics LLC
  • 15.4. SpheriTech Ltd
  • 15.5. Kalocyte, Inc.
  • 15.6. OPKO Health, Inc.
  • 15.7. Prolong Pharmaceuticals, LLC
  • 15.8. VisusMed Medical Center
  • 15.9. Boston Pharmaceuticals, Inc

16. Strategic Recommendations

17. About Us & Disclaimer